Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2019

View Archived Issues

Autophagy rejuvenates memory

Microtubules implicated in ALS

First patient enrolled in phase II study of ImaginAb's CD8+ T-cell Immuno-PET imaging agent

Virulence factor suppresses immune response in chronic P. aeruginosa infection

Updated results presented from phase II FAST study of zolbetuximab

Anlotinib significantly improves PFS and DCR in patients with pretreated advanced ESCC

Results in patients with relapsed gastric cancer presented from the phase II MEDIOLA study

Data presented from 4-year follow-up of phase I/IIa study of NTCELL in Parkinson's disease

Spero Therapeutics initiates phase I study of SPR-720 in healthy volunteers

European Commission approves label extension for Orkambi to include children aged 2-5 years

Phase II results presented for durvalumab in patients with esophageal and GEJ cancer

Phase II trial of JKB-122 in refractory autoimmune hepatitis meets endpoints

Ferring and Karolinska Institutet extend human microbiome collaboration

Toray studies TGF-beta1 inhibitor TRK-250 in phase I for IPF

Pompeu Fabra University and Esteve begin RIBOPAIN project in neuropathic pain

Acacia reports cardiac safety data for antiemetic Barhemsys

MacroGenics opens phase I study of MGD-019 in unresectable or metastatic cancer

Peiminine induces apoptosis in HCC HepG2 cells through extrinsic and intrinsic apoptotic pathways

STRAP as a biomarker of osteosarcoma progression

TAS-102 in combination with oxaliplatin safe in patients with mCRC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...